COVID-19 Drug Interactions

被引:4
|
作者
Surmelioglu, Nursel [1 ]
Demirkan, Kutay [2 ]
机构
[1] Cukurova Univ, Dept Clin Pharm, Fac Pharm, Adana, Turkey
[2] Hacettepe Univ, Dept Clin Pharm, Fac Pharm, Ankara, Turkey
来源
关键词
COVID-19; Drug Interactions; Lopinavir/Ritonavir; Hydroxychloroquine; Polypharmacy;
D O I
10.37678/dcybd.2020.2409
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Elderly patients are at high risk of corona virus disease 2019 (COVID-2019) infection and severe COVID-19 patients are treated in intensive care units (ICU). Drug-drug interaction risk increased to 100% with eight or more medication use. Comorbidities in both elderly and ICU patients leading to polypharmacy and a higher risk for drug-drug interactions. Also, the organ dysfunctions due to COVID-19 may alter the pharmacokinetics of the drugs which may influence the severity of drug interactions. The severity, mechanisms, onset of action and clinical significance of the drug-drug interactions may vary. Detailed information on COVID-19 drug interactions is reported by The Liverpool Drug Interaction Group, however this paper was aimed to provide a quick guidance on these interactions for the clinicians. During the management of COVID-19, possibility of drug-drug interactions should be considered by clinicians to avoid any negative outcomes in the treatment process.
引用
收藏
页码:43 / 45
页数:3
相关论文
共 50 条
  • [2] Drug Interactions of Psychiatric and COVID-19 Medications
    Mohebbi, Niayesh
    Talebi, Ali
    Moghadamnia, Marjan
    Taloki, Zahra Nazari
    Shakiba, Alia
    [J]. BASIC AND CLINICAL NEUROSCIENCE, 2020, 11 (02) : 185 - 200
  • [3] Drug–Drug Interactions in Patients with COVID-19 in Nursing Homes
    Florian Correard
    Anne-Laure Couderc
    Robin Arcani
    Joris Weiland
    Anais Courcier
    Charlotte Berard
    Charlène Miola
    Julie Berbis
    Patrick Villani
    Aurélie Daumas
    [J]. Drugs & Aging, 2021, 38 : 633 - 635
  • [4] Drug-drug interactions between COVID-19 drug therapies and antidepressants
    Davoutis, Efstathia
    Panou, Chrysa
    Stachika, Nikolina
    Dalla, Christina
    Kokras, Nikolaos
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (12) : 937 - 950
  • [5] Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
    Preskorn, Sheldon H.
    Quadri, Syeda
    [J]. JOURNAL OF PSYCHIATRIC PRACTICE, 2020, 26 (06) : 485 - 492
  • [6] POTENTIAL DRUG-DRUG INTERACTIONS IN HOSPITALIZED PATIENTS WITH COVID-19
    Szkutnik-Fiedler, Danuta
    Kwiatkowski, Filip
    Chomej, Monika
    Kolodziej, Dorota
    Michalak, Michal
    Grzeskowiak, Edmund
    Szalek, Edyta
    [J]. ACTA POLONIAE PHARMACEUTICA, 2023, 80 (02): : 277 - 287
  • [7] Drug-drug Interactions: An Overlooked Dimension of the COVID-19 Pandemic
    Beninger, Paul
    [J]. CLINICAL THERAPEUTICS, 2023, 45 (05) : 387 - 388
  • [8] Drug-Drug Interactions in Patients with COVID-19 in Nursing Homes
    Correard, Florian
    Couderc, Anne-Laure
    Arcani, Robin
    Weiland, Joris
    Courcier, Anais
    Berard, Charlotte
    Miola, Charlene
    Berbis, Julie
    Villani, Patrick
    Daumas, Aurelie
    [J]. DRUGS & AGING, 2021, 38 (07) : 633 - 635
  • [9] Elucidation of Teicoplanin Interactions with Drug Targets Related to COVID-19
    Azam, Faizul
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (07):
  • [10] Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment
    Roden, Dan M.
    Harrington, Robert A.
    Poppas, Athena
    Russo, Andrea M.
    [J]. CIRCULATION, 2020, 141 (24) : E906 - E907